BMN 270 is one of the most important drugs in Biomarin's research pipeline and key driver of future revenue and earnings.
United Technologies is taking share from competitors like General Electirc.
DuPont shares were on the rise Tuesday following its latest quarterly results.
Gilead's stock trades at a discount to other biotech peers because its drug research pipeline lacks the blockbusters needed to make up for slowing sales from its hepatitis C franchise.
European regulators have delayed PTC Therapeutics' request for permanent approval of its Duchenne muscular dystrophy drug Translarna.
A slew of corporate earnings and closely watched Federal Reserve meeting are in focus for the week of July 25.
Tesla CEO Elon Musk is a visionary who thinks big, but don't trust his numbers, says Jim Cramer.